Friday’s move means another months-long delay for the shots.
The Food and Drug Administration had urged Pfizer to apply before its study was even finished on whether the youngsters needed two shots or three.
The agency cited the toll the omicron variant has taken on children. But Friday, the FDA reversed course and said it needed to see how well three shots worked.
Pfizer said in a statement that it expected that data by early April.